NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Lucky minions!

You know rGBM patients on average have five to seven months. There is a collaboration trial between AZN and Jonsson Comprehensive Cancer Center with Timothy Cloughesy as PI. The trial was finished enrolling the end of 2020. The completion date was 2021-11-01 originally. But they keep extending the completion date which means rGBM patients are alive. Currently the completion date October 1.

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma
https://clinicaltrials.gov/study/NCT03732352

The trial is about a drug called Tagrisso which inhibits an specific overexpressed mutated gene EGFR. The following are the data from 29 GBM patients from the p3 trial. Avastin is the blockbuster cancer drug from Genentech which targets VEGFA. We can see clearly that EGFR is on average more overexpressed than VEGFA. Seems to me EGFR is a better target than VEGFA which might explain why the rGBM patients in the trial have better OS.

I suspect Timothy Cloughesy had the first-hand solid data on whether inhibiting EGFR can be a good treatment for GBM/rGBM patients which explains why he founded a company Katmai Pharmaceuticals developing small molecule drug targeting EGFR. The drug was licensed to Erasca and had Orphan drug designation and is under clinical trial now.

Let your minions read my post. If they don't think it is nonsense, they might buy more. Those who are convinced and buy more can buy me a beer later. LoL.



https://www.uclahealth.org/news/release/potential-glioblastoma-treatment-has-roots-ucla-graduate

https://investors.erasca.com/news-releases/news-release-details/erasca-granted-fda-orphan-drug-designation-cns-penetrant-egfr

https://investors.erasca.com/news-releases/news-release-details/erasca-granted-fda-fast-track-designation-cns-penetrant-egfr